MarketCapExport financials
Harpoon Therapeutics (HARP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Harpoon Therapeutics Balance Sheet 2022-2011 | HARP
Brief overview of Harpoon Therapeutics's balance sheet strength
This overview follows the five latest available annual observations between 2018 and 2022.
The asset base decreased -28.1%, from $102.6 million to $73.7 million. Resources became smaller over the five periods.
Liability growth of +158% exceeded asset growth of -28.1%, increasing reliance on outside funding.
Internal capital represents 7.3% of the balance sheet versus -52.1% five periods ago. The cushion is thin.
Net debt moved below zero to -$35.6 million, reflecting surplus cash over debt.
Cash represents 70% of assets versus 87.2% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$352.5 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
Harpoon Therapeutics has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Harpoon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-35.6 M | -32.5 M | -7.66 M | -73.8 M | -89.5 M | -29.4 M | 1.33 M | - | - | - | - | - |
Long Term Debt |
13.6 M | 10.5 M | 12.3 M | 13.7 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.42 M | 1.65 M | 1.2 M | 1.22 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 59.9 M | 144 M | 51.9 M | 15 M | - | - | - | - | - |
Total Current Liabilities |
52.4 M | 59.1 M | 47.9 M | 22.5 M | 11.9 M | 6.92 M | - | - | - | - | - | - |
Total Liabilities |
68.3 M | 97.4 M | 118 M | 82.4 M | 26.5 M | 19 M | 18.8 M | - | - | - | - | - |
Deferred Revenue |
30.9 M | 37.5 M | 31.3 M | 11.2 M | 4.25 M | 4.25 M | - | - | - | - | - | - |
Retained Earnings |
-353 M | -285 M | -168 M | -118 M | -62.6 M | -35.2 M | -18.4 M | - | - | - | - | - |
Total Assets |
73.7 M | 155 M | 172 M | 177 M | 103 M | 31.9 M | 8.38 M | - | - | - | - | - |
Cash and Cash Equivalents |
51.6 M | 44.7 M | 21.2 M | 88.7 M | 89.5 M | 29.4 M | 985 K | - | - | - | - | - |
Book Value |
5.4 M | 58.1 M | 53.8 M | 94.2 M | 76.1 M | 12.9 M | -10.4 M | - | - | - | - | - |
Total Shareholders Equity |
5.4 M | 58.1 M | 53.8 M | 94.2 M | -53.5 M | -26.9 M | -10.4 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Harpoon Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
11.5 M | 12.3 M | 12.8 M | 13.6 M | 9.14 M | 9.63 M | 10.1 M | 10.5 M | 11 M | 11.4 M | 11.8 M | 12.3 M | 12.7 M | 13.1 M | 13.4 M | 13.7 M | 14.1 M | 14.4 M | 14.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
43 M | 60.2 M | 80.1 M | 68.3 M | 66.6 M | 82.3 M | 91.1 M | 97.4 M | 97.7 M | 105 M | 159 M | 118 M | 123 M | 125 M | 79.2 M | 82.4 M | 35.2 M | 34.5 M | 33.3 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 4.45 M | 22.4 M | 30.9 M | 34 M | 36.5 M | 36.9 M | 37.5 M | 38.1 M | 34.8 M | 30.8 M | 31.3 M | 31.6 M | 27.1 M | 13.9 M | 11.2 M | 4.08 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-365 M | -363 M | -364 M | -353 M | -334 M | -322 M | -305 M | -285 M | -263 M | -247 M | -230 M | -168 M | -157 M | -143 M | -131 M | -118 M | -104 M | -88 M | -76.2 M | -62.6 M | -62.6 M | -62.6 M | -62.6 M | -35.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
47.6 M | 63.2 M | 80.8 M | 73.7 M | 83.5 M | 109 M | 132 M | 155 M | 175 M | 196 M | 261 M | 172 M | 183 M | 197 M | 162 M | 177 M | 142 M | 157 M | 167 M | 103 M | 103 M | 103 M | 103 M | 31.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
17.7 M | 32.8 M | 61.4 M | 51.6 M | 50.4 M | 68.6 M | 50.7 M | 44.7 M | 43 M | 77.4 M | 71.3 M | 21.2 M | 22.7 M | 34.7 M | 36.2 M | 88.7 M | 56.8 M | 52.1 M | 95.9 M | 89.5 M | 89.5 M | 89.5 M | 89.5 M | 29.4 M | - | - | - | 985 K | - | - | - | 2.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
4.54 M | 3 M | 715 K | 5.4 M | 16.9 M | 26.6 M | 41.4 M | 58.1 M | 77 M | 90.9 M | 102 M | 53.8 M | 60.7 M | 71.9 M | 83.3 M | 94.2 M | 107 M | 122 M | 134 M | 76.1 M | 76.1 M | 76.1 M | 76.1 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
4.54 M | 3 M | 715 K | 5.4 M | 16.9 M | 26.6 M | 41.4 M | 58.1 M | 77 M | 90.9 M | 102 M | 53.8 M | 60.7 M | 71.9 M | 83.3 M | 94.2 M | 107 M | 122 M | 134 M | -53.5 M | -53.5 M | -53.5 M | -53.5 M | -26.9 M | - | - | - | -10.4 M | - | - | - | -6.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Harpoon Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Israel
Australia
Britain
Russia
Schweiz
Niderland
France
